38
April 18, 2023 | 18:26

Sandra Bond Chapman Ph.D. and the Importance of Lifelong Brain Health - Part 1

Want to improve your brain’s performance? Why not? You’re using it anyway. Find out the latest from Dr. Sandi Bond Chapman, Founder and Chief Director

LISTEN NOW
37
April 4, 2023 | 23:33

Rebecca Chopp, Ph.D., and Her Unexpected Alzheimer’s Diagnosis (part 2)

Rebecca Chopp, Ph.D., built a life around a profession that prized the mind and then was unexpectedly diagnosed with Alzheimer's disease. Dr. Chopp, former Chancellor

LISTEN NOW
36
March 21, 2023 | 21:43

Rebecca Chopp, Ph.D., and Her Unexpected Alzheimer’s Diagnosis (part 1)

Rebecca Chopp, Ph.D., built a life around a profession that prized the mind and then was unexpectedly diagnosed with Alzheimer's disease. Hear how Dr. Chopp

LISTEN NOW
35
March 7, 2023 | 14:44

Dr. Rudy Tanzi -The Latest on Alzheimer's Drugs (part 2)

BrainStorm host Meryl Comer talks with Dr. Rudy Tanzi, Vice-Chair of Neurology at Massachusetts General Hospital, Co-Director of the McCance Center for Brain Health and Professor at Harvard Medical School.
LISTEN NOW
34
February 21, 2023 | 20:06

Rudy Tanzi and the Latest Alzheimer’s Drugs - part 1

Will 2023 be a boom or bust year for new Alzheimer’s drugs? 

In this episode of BrainStorm host Meryl Comer talks with Dr. Rudy Tanzi

LISTEN NOW
33
February 7, 2023 | 13:55

George Vradenburg – The Future of Alzheimer’s Advocacy Part 2

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What

LISTEN NOW
32
January 17, 2023 | 16:23

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What

LISTEN NOW
January 04, 2023

30 Years On, Are We Winning the Fight Against Alzheimer’s?

Lecanemab, Donanemab, Drug-Free Strategies Emerge as New Weapons Against Dementia By Suzanne Leigh UC San Francisco experts say that we have reached a pivotal point in Alzheimer’s disease research, 30 years after the first pharmaceutical came to market. On Jan. 6, 2023, the Food and Drug Administration is expected to give accelerated approval of lecanemab – one of the first drugs to attract widespread enthusiasm among neurologists, after showing positive phase 3 results in slowing the progression of early-stage disease. The UCSF-tested drug is a monoclonal antibody, a lab-made protein, that targets amyloid plaques that accumulate between neurons and disrupt
31
December 20, 2022 | 14:40

Ken Dychtwald - Breakthroughs at the Tipping Point

Rising longevity and the aging of boomers worldwide are radically altering both the demographic landscape and every aspect of our personal, social, financial, and political

LISTEN NOW
December 15, 2022

A-LIST Pulse of the Community Vol 14, December 2022

The mission of the A-LIST is to use survey results to make life better for the broader Alzheimer’s and dementia community. UsAgainstAlzheimer’s makes sure policymakers, researchers, healthcare providers, drug developers, insurers and others who serve this community understand and consider A-LIST member insights about the Alzheimer’s and dementia journey when making decisions that affect those living with the disease and caregivers. Read the full newsletter here.
Subscribe to